119 related articles for article (PubMed ID: 36412395)
21. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.
Dogan N; King S; Emami B; Mohideen N; Mirkovic N; Leybovich LB; Sethi A
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1480-91. PubMed ID: 14630288
[TBL] [Abstract][Full Text] [Related]
22. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
23. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
Sun H; Liu C; Zhang J; Yang G; Han D; Liu T; Huang W; Li B
Radiother Oncol; 2022 Jul; 172():140-146. PubMed ID: 35101460
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
[TBL] [Abstract][Full Text] [Related]
26. [Intensity-modulated radiation therapy for head and neck cancers with bilateral irradiation of the neck : preliminary results].
Lapeyre M; Marchesi V; Mege A; Aletti P; Graff P; Racadot S; Noel A; Marchal C
Cancer Radiother; 2004 Jun; 8(3):134-47. PubMed ID: 15217581
[TBL] [Abstract][Full Text] [Related]
27. Swallowing sparing intensity modulated radiotherapy versus standard parotid sparing intensity-modulated radiotherapy for treatment of head and neck cancer: a randomized clinical trial.
Ashour MG; Shouman TH; Hassouna AH; Mokhtar MH; Emad El Din R; Youssef AA; Gomaa MM; Abdelgeleel S
Acta Oncol; 2022 Feb; 61(2):134-140. PubMed ID: 35000532
[TBL] [Abstract][Full Text] [Related]
28. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial.
Gupta T; Sinha S; Ghosh-Laskar S; Budrukkar A; Mummudi N; Swain M; Phurailatpam R; Prabhash K; Agarwal JP
Radiat Oncol; 2020 Sep; 15(1):218. PubMed ID: 32938468
[TBL] [Abstract][Full Text] [Related]
29. A prospective, comparative analysis of acute toxicity profile between three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in locally advanced head and neck cancer patients.
Kucha N; Soni TP; Jakhotia N; Patni N; Singh DK; Gupta AK; Sharma LM; Goyal J
Cancer Treat Res Commun; 2020; 25():100223. PubMed ID: 33120316
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant simultaneous integrated boost IMRT for patients with intermediate- and high-risk head and neck cancer: outcome, toxicities and patterns of failure.
Stromberger C; Jann D; Becker ET; Raguse JD; Tinhofer I; Marnitz S; Budach V
Oral Oncol; 2014 Nov; 50(11):1114-21. PubMed ID: 25204515
[TBL] [Abstract][Full Text] [Related]
31. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
[TBL] [Abstract][Full Text] [Related]
33. A Study to Assess the Dosimetric Impact of the Anatomical Changes Occurring in the Parotid Glands and Tumour Volume during Intensity Modulated Radiotherapy using Simultaneous Integrated Boost (IMRT-SIB) in Head and Neck Squamous Cell Cancers.
Ghosh A; Gupta S; Johny D; Vidyadhar Bhosale V; Pal Singh Negi M
Cancer Med; 2021 Aug; 10(15):5175-5190. PubMed ID: 34159749
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
[TBL] [Abstract][Full Text] [Related]
36. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
[TBL] [Abstract][Full Text] [Related]
37. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
Vlacich G; Diaz R; Thorpe SW; Murphy BA; Kirby W; Sinard RJ; Shakhtour B; Shyr Y; Murphy P; Netterville JL; Yarbrough WG; Cmelak AJ
Oncologist; 2012; 17(5):673-81. PubMed ID: 22550060
[TBL] [Abstract][Full Text] [Related]
38. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
[TBL] [Abstract][Full Text] [Related]
39. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
